PENNER HARRY JR 4
4 · Celldex Therapeutics, Inc. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Celldex (CLDX) Director Harry Penner Receives 26,000-Share Option Award
What Happened
- Harry Penner Jr., a director of Celldex Therapeutics (CLDX), was granted a derivative award of 26,000 shares on 2026-06-25. The grant is recorded at $0.00 in the Form 4 and is reported as an acquisition via a derivative instrument (an option).
Key Details
- Transaction date: 2026-06-25; Form 4 filed: 2026-06-29.
- Transaction type/code: A (grant/award or other acquisition); 26,000 derivative shares at $0.00.
- Footnote: F1 clarifies this represents an option granted under Celldex’s 2021 Omnibus Equity Incentive Plan.
- Shares owned after transaction: not specified in the filing.
- Timeliness: filing date is 2026-06-29 (the Form 4 was filed within the normal two-business-day reporting window for most insider reports).
Context
- This filing reflects an option grant (a compensation award), not a cash purchase of stock or an exercise/sale. Option grants are common director compensation and do not by themselves indicate an immediate buy or sell decision.
Insider Transaction Report
Form 4
PENNER HARRY JR
Director
Transactions
- Award
Non-Qualified Stock Option (right to buy)
[F1]2026-06-25+26,000→ 26,000 totalExercise: $34.09From: 2027-06-25Exp: 2036-06-25→ Common Stock (26,000 underlying)
Footnotes (1)
- [F1]Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Signature
/s/ Sam Martin, attorney-in-fact for Harry H. Penner, Jr.|2026-06-29